Details of the Drug

General Information of Drug (ID: DMPHZQE)

Drug Name
Chlorpropamide
Synonyms
Adiaben; Asucrol; Bioglumin; Catanil; Chlorodiabina; Chloronase; Chloropropamide; Chlorporpamide; Chlorpropamid; Chlorpropamidum; Clorpropamid; Clorpropamida; Clorpropamide; Diabaril; Diabechlor; Diabenal; Diabenese; Diabeneza; Diabetoral; Diabexan; Diabinese; Dynalase; Glisema; Glucamide; Insogen; Insulase; Meldian; Melitase; Mellinese; Millinese; Oradian; Prodiaben; Stabinol; Apotex Brand of Chlorpropamide; Byk Gulden Brand of Chlorpropamide; CHLORPROPAMIDE USP; Clorpropamide [DCIT]; Clorpropamide [Italian];Dia benese; Diamel Ex; Farmasierra Brand of Chlorpropamide; Pfizer Brand of Chlorpropamide; C 1290; P 607; Apo-Chlorpropamide; Chlorpropamide Bp/ Usp; Chlorpropamidum [INN-Latin]; Clorpropamida [INN-Spanish]; Diabet-Pages; Diabinese (TN); Novo-Propamide; U-3818; U-9818; Chlorpropamide [INN:BAN:JAN]; Chlorpropamide (JP15/USP/INN); N3-Butyl-N1-p-chlorobenzenesulfonylure a; N3-Butyl-N1-p-chlorobenzenesulfonylurea; N-Propyl-N'-p-chlorophenylsulfonylcarbamide; N-Propyl-N'-p-chlorphenylsulfonylcarbamide; N-propyl-N'-p-chlorophenylsu lfonylcarbamide; N-(4-Chlorophenylsulfonyl)-N'-propylurea; N-(p-Chlorobenzenesulfonyl)-N'-propylurea; N-Propyl-N'-(p-chlorobenzenesulfonyl)urea; 1-((p-Chlorophenyl)sulfonyl)-3-propylurea; 1-(4-Chlorophenylsulfonyl)-3-propylurea; 1-(4-chlorophenyl)sulfonyl-3-propylurea; 1-(p-Chlorobenzenesulfonyl)-3-propylurea; 1-(p-Chlorobenzensulfonyl)-3-propylurea; 1-(p-Chlorophenylsulfonyl)-3-propylurea; 1-(para-Chlorophenylsulfonyl)-3-propylurea; 1-Propyl-3-(p-chlorobenzenesulfonyl)urea; 1-[(4-chlorobenzene)sulfonyl]-3-propylurea; 1-[p-Chlorobenzenesulfonyl]-3-propylurea; 1-p-Chlorophenyl-3-(propylsulfonyl)urea; 4-Chloro-4-((propylamino)carbonyl)benzenesulfonamide; 4-Chloro-N-((propylamino)carbonyl)benzenesulfonamide; 4-chloro-N-(propylcarbamoyl)benzenesulfonamide; 4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide
Indication
Disease Entry ICD 11 Status REF
Non-insulin dependent diabetes 5A11 Approved [1], [2], [3]
Therapeutic Class
Hypoglycemic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 276.74
Topological Polar Surface Area (xlogp) 2.3
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Bioavailability
95% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.045 mL/min/kg [5]
Elimination
20% of drug is excreted from urine in the unchanged form [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 36 hours [5]
Metabolism
The drug is metabolized via the liver [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 45.16814 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.03% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.19 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 2.2 mg/mL [6]
Chemical Identifiers
Formula
C10H13ClN2O3S
IUPAC Name
1-(4-chlorophenyl)sulfonyl-3-propylurea
Canonical SMILES
CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl
InChI
InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)
InChIKey
RKWGIWYCVPQPMF-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2727
ChEBI ID
CHEBI:3650
CAS Number
94-20-2
DrugBank ID
DB00672
TTD ID
D00BCP
VARIDT ID
DR00478
INTEDE ID
DR0311
ACDINA ID
D00125

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Inward rectifier potassium channel Kir1.2 (KCNJ10) TTG140O KCJ10_HUMAN Blocker [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [10]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Chlorpropamide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Moderate Decreased absorption of Chlorpropamide due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [34]
Tromethamine DMOBLGK Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Chlorpropamide caused by Tromethamine mediated altered urine pH. Acidosis [5C73] [35]
Nateglinide DMLK2QH Moderate Decreased metabolism of Chlorpropamide caused by Nateglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [36]
Arn-509 DMT81LZ Moderate Increased metabolism of Chlorpropamide caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [37]
Oxymetholone DMFXUT8 Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Oxymetholone. Aplastic anaemia [3A70] [38]
Sulfamethoxazole DMB08GE Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [38]
Alpelisib DMEXMYK Moderate Increased metabolism of Chlorpropamide caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [39]
Fluoxymesterone DMUHCF1 Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Fluoxymesterone. Breast cancer [2C60-2C6Y] [40]
Fenofibric acid DMGO2MC Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Fenofibric acid. Cardiovascular disease [BA00-BE2Z] [40]
Phenylbutazone DMAYL0T Moderate Decreased metabolism of Chlorpropamide caused by Phenylbutazone. Chronic pain [MG30] [41]
Ketoprofen DMRKXPT Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Ketoprofen. Chronic pain [MG30] [40]
Anisindione DM2C48U Moderate Increased plasma concentration of Chlorpropamide and Anisindione due to competitive binding of plasma proteins. Coagulation defect [3B10] [42]
Ardeparin DMYRX8B Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Ardeparin. Coronary thrombosis [BA43] [40]
Mifepristone DMGZQEF Moderate Decreased metabolism of Chlorpropamide caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [43]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Chlorpropamide caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [44]
MK-8228 DMOB58Q Moderate Increased metabolism of Chlorpropamide caused by MK-8228 mediated induction of CYP450 enzyme. Cytomegaloviral disease [1D82] [45]
Sertraline DM0FB1J Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Sertraline. Depression [6A70-6A7Z] [40]
Vilazodone DM4LECQ Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Vilazodone. Depression [6A70-6A7Z] [40]
Paroxetine DM5PVQE Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Paroxetine. Depression [6A70-6A7Z] [40]
Selegiline DM6034S Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Selegiline. Depression [6A70-6A7Z] [40]
Vortioxetine DM6F1PU Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Vortioxetine. Depression [6A70-6A7Z] [40]
Isocarboxazid DMAF1NB Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Isocarboxazid. Depression [6A70-6A7Z] [40]
Escitalopram DMFK9HG Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Escitalopram. Depression [6A70-6A7Z] [40]
Tranylcypromine DMGB5RE Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Tranylcypromine. Depression [6A70-6A7Z] [38]
Phenelzine DMHIDUE Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Phenelzine. Depression [6A70-6A7Z] [40]
SODIUM CITRATE DMHPD2Y Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Chlorpropamide caused by SODIUM CITRATE mediated altered urine pH. Discovery agent [N.A.] [35]
PMID28870136-Compound-49 DMTUC9E Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and PMID28870136-Compound-49. Discovery agent [N.A.] [40]
Oxcarbazepine DM5PU6O Moderate Decreased metabolism of Chlorpropamide caused by Oxcarbazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [46]
Brivaracetam DMSEPK8 Minor Decreased metabolism of Chlorpropamide caused by Brivaracetam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [37]
Mefenamic acid DMK7HFI Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Mefenamic acid. Female pelvic pain [GA34] [40]
Miconazole DMPMYE8 Major Decreased metabolism of Chlorpropamide caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [40]
Sunitinib DMCBJSR Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Sunitinib. Gastrointestinal stromal tumour [2B5B] [40]
Sulfinpyrazone DMEV954 Moderate Decreased renal excretion of Chlorpropamide caused by Sulfinpyrazone. Gout [FA25] [41]
Rifampin DMA8J1G Moderate Increased metabolism of Chlorpropamide caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [47]
Rifapentine DMCHV4I Moderate Increased metabolism of Chlorpropamide caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [48]
Etravirine DMGV8QU Moderate Decreased metabolism of Chlorpropamide caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [49]
Gemfibrozil DMD8Q3J Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Gemfibrozil. Hyper-lipoproteinaemia [5C80] [40]
Fenofibrate DMFKXDY Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Fenofibrate. Hyper-lipoproteinaemia [5C80] [40]
Captopril DM458UM Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Captopril. Hypertension [BA00-BA04] [40]
Methyldopa DM5I621 Minor Decreased metabolism of Chlorpropamide caused by Methyldopa. Hypertension [BA00-BA04] [50]
Perindopril DMOPZDT Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Perindopril. Hypertension [BA00-BA04] [40]
Quinapril DMR8H31 Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Quinapril. Hypertension [BA00-BA04] [40]
Lisinopril DMUOK4C Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Lisinopril. Hypertension [BA00-BA04] [40]
Sodium acetate anhydrous DMH21E0 Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Chlorpropamide caused by Sodium acetate anhydrous mediated altered urine pH. Hypo-osmolality/hyponatraemia [5C72] [35]
Probenecid DMMFWOJ Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Probenecid. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [40]
Balsalazide DMO091F Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Balsalazide. Indeterminate colitis [DD72] [40]
Meclofenamic acid DM05FXR Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [38]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Chlorpropamide and Porfimer Sodium. Lung cancer [2C25] [51]
PF-06463922 DMKM7EW Moderate Increased metabolism of Chlorpropamide caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [46]
Sulphadoxine DMZI2UF Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Sulphadoxine. Malaria [1F40-1F45] [38]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Chlorpropamide caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [46]
Mecasermin DM1O3BY Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Mecasermin. Multiple structural anomalies syndrome [LD2F] [40]
Naproxen DMZ5RGV Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Naproxen. Osteoarthritis [FA00-FA05] [40]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Chlorpropamide caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [52]
Aspirin DM672AH Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Aspirin. Pain [MG30-MG3Z] [38]
Etodolac DM6WJO9 Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Etodolac. Pain [MG30-MG3Z] [40]
Diflunisal DM7EN8I Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Diflunisal. Pain [MG30-MG3Z] [40]
Ibuprofen DM8VCBE Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Ibuprofen. Pain [MG30-MG3Z] [40]
Safinamide DM0YWJC Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Safinamide. Parkinsonism [8A00] [40]
Rasagiline DM3WKQ4 Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Rasagiline. Parkinsonism [8A00] [40]
Ranitidine DM0GUSX Moderate Decreased absorption of Chlorpropamide due to altered gastric pH caused by Ranitidine. Peptic ulcer [DA61] [53]
Esomeprazole DM7BN0X Minor Decreased metabolism of Chlorpropamide caused by Esomeprazole mediated inhibition of CYP450 enzyme. Peptic ulcer [DA61] [54]
Famotidine DMRL3AB Moderate Decreased absorption of Chlorpropamide due to altered gastric pH caused by Famotidine. Peptic ulcer [DA61] [53]
Choline salicylate DM8P137 Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Choline salicylate. Postoperative inflammation [1A00-CA43] [38]
Bromfenac DMKB79O Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Bromfenac. Postoperative inflammation [1A00-CA43] [38]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Chlorpropamide caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [55]
Enzalutamide DMGL19D Moderate Increased metabolism of Chlorpropamide caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [56]
Salsalate DM13P4C Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Salsalate. Rheumatoid arthritis [FA20] [40]
Meloxicam DM2AR7L Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Meloxicam. Rheumatoid arthritis [FA20] [40]
Oxaprozin DM9UB0P Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Oxaprozin. Rheumatoid arthritis [FA20] [40]
Flurbiprofen DMGN4BY Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Flurbiprofen. Rheumatoid arthritis [FA20] [40]
Sulfasalazine DMICA9H Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Sulfasalazine. Rheumatoid arthritis [FA20] [40]
Leflunomide DMR8ONJ Moderate Decreased metabolism of Chlorpropamide caused by Leflunomide mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [57]
Salicyclic acid DM2F8XZ Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Salicyclic acid. Seborrhoeic dermatitis [EA81] [38]
Ifosfamide DMCT3I8 Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [40]
Methyltestosterone DMWLFGO Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Methyltestosterone. Solid tumour/cancer [2A00-2F9Z] [40]
Warfarin DMJYCVW Moderate Increased plasma concentration of Chlorpropamide and Warfarin due to competitive binding of plasma proteins. Supraventricular tachyarrhythmia [BC81] [42]
Pramlintide DM0EZ9Q Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Pramlintide. Type-1/2 diabete [5A10-5A11] [40]
Olsalazine DMZW9HA Moderate Increased risk of hypoglycemia by the combination of Chlorpropamide and Olsalazine. Ulcerative colitis [DD71] [40]
⏷ Show the Full List of 79 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Aminoethanoic acid E00025 750 Buffering agent; Disintegrant; Lyophilization aid
Calcium carbonate E00198 10112 Binding agent; Buffering agent; Diluent; Opacifying agent
FD&C blue no. 1 E00263 19700 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Carmellose sodium E00625 Not Available Disintegrant
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Chlorpropamide 100 mg tablet 100 mg Oral Tablet Oral
Chlorpropamide 250 mg tablet 250 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6801).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 088548.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 BDDCS applied to over 900 drugs
7 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Effect of the chlorpropamide and fructose-1,6-bisphosphate of soluble TNF receptor II levels. Pharmacol Res. 2004 May;49(5):449-53.
10 Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br J Clin Pharmacol. 2005 May;59(5):552-63.
11 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
12 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
13 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
14 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
15 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
16 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
17 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
18 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
19 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
20 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
21 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
22 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
23 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
24 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
25 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
26 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
27 Triggering and amplification of insulin secretion by dimethyl alpha-ketoglutarate, a membrane permeable alpha-ketoglutarate analogue. Eur J Pharmacol. 2009 Apr 1;607(1-3):41-6.
28 Bepridil, an antiarrhythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotection. J Pharmacol Exp Ther. 2006 Jan;316(1):182-8.
29 Hydroxyl-substituted sulfonylureas as potent inhibitors of specific [3H]glyburide binding to rat brain synaptosomes. Bioorg Med Chem. 2003 May 1;11(9):2099-113.
30 Inhibition of ATP-activated potassium channels exerts pressor effects and improves survival in a rat model of severe hemorrhagic shock. Shock. 1996 Jun;5(6):391-4.
31 Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. Biochem Pharmacol. 2007 Jun 1;73(11):1842-51.
32 Coupling between proximal tubular transport processes. Studies with ouabain, SITS and HCO3-free solutions. Pflugers Arch. 1977 Apr 25;368(3):245-52.
33 Cardioselective K(ATP) channel blockers derived from a new series of m-anisamidoethylbenzenesulfonylthioureas. J Med Chem. 2001 Mar 29;44(7):1085-98.
34 Kivisto KT, Neuvonen PJ "Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide." Eur J Clin Pharmacol 42 (1992): 675-80. [PMID: 1623912]
35 Kivisto KT, Neuvonen PJ "Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide." Eur J Clin Pharmacol 40 (1991): 383-6. [PMID: 1646724]
36 Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
37 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
38 Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
39 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
40 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
41 Mahfouz M, Abdel-Maguid R, El-Dakhakhny M "Potentiation of the hypoglycaemic action of tolbutamide by different drugs." Arzneimittelforschung 20 (1970): 120-2. [PMID: 5467602]
42 Hansen JM, Christensen LK "Drug interactions with oral sulphonylurea hypoglycaemic drugs." Drugs 13 (1977): 24-34. [PMID: 401727]
43 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
44 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
45 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
46 Cerner Multum, Inc. "Australian Product Information.".
47 Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
48 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
49 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
50 Gachalyi B, Tornyossy, Vas A, Kaldor A "Effect of alphamethyldopa on the half-lives of antipyrine, tolbutamide and D-glucaric acid excretion in man." Int J Clin Pharmacol Ther Toxicol 18 (1980): 133-5. [PMID: 6103880]
51 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
52 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
53 Dey NG, Castleden CM, Ward J, et al "The effect of cimetidine on tolbutamide kinetics." Br J Clin Pharmacol 16 (1983): 438-40. [PMID: 6626438]
54 Humphries TJ "Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole." Dig Dis Sci 36 (1991): 1665-9. [PMID: 1748033]
55 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
56 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
57 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.